Skip to content
Screener

Accounts Payable at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$8.92M+54.3%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$7.15M+28.1%
Septerna, Inc. logo
Septerna, Inc.SEPN
$7.46M+71.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$6.84M+213%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$1.24M-49.4%
Regenxbio logo
RegenxbioRGNX
$15.55M-28.2%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemMay 31,2026November 30,2025
Total assets$535,540$688,135
Liabilities and stockholdersʼ equity
Current liabilities:
Accounts payable$12,208$11,215
Accrued expenses and other current liabilities43,26754,852
Operating lease liabilities, current3,2212,824
Deferred revenue, current13,32417,580
Total current liabilities72,02086,471

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s accounts payable?
Nurix Therapeutics, Inc. (NRIX) reported accounts payable of $12.21M in Q1 2026.
How has Nurix Therapeutics, Inc.'s accounts payable changed year-over-year?
Nurix Therapeutics, Inc.'s accounts payable increased by 105.0% year-over-year, from $5.95M to $12.21M.
What is the long-term trend for Nurix Therapeutics, Inc.'s accounts payable?
Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s accounts payable has grown at a 26.9% compound annual growth rate (CAGR), from $3.41M to $11.22M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Ask your AI about Nurix Therapeutics, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude